Table 1.
Clinical characteristics of all participants with human immunodeficiency virus type 1.
| NK + ART | ART | |||
| Variable | (n = 10) | (n = 10) | Z | P |
| Female/male, n | 0/10 | 0/10 | – | – |
| Age (years) | 56 (53–58) | 55 (47–62) | <0.001 | >0.999 |
| CD4+ T-cell count (cells/μL) | 151 (110–178) | 124 (118–192) | 0.340 | 0.733 |
| Nadir CD4 count (cells/μL) | 18 (7–69) | 27 (17–37) | 0.340 | 0.734 |
| CD8+ T-cell count (cells/μL) | 586 (270–965) | 642 (441–787) | 0.794 | 0.427 |
| CD4/CD8 ratio | 0.24 (0.16–0.41) | 0.24 (0.17–0.32) | 0.643 | 0.521 |
| Plasma HIV RNA (copies/mL) | Undetectable | Undetectable | – | – |
| Years of ART | 3.58 (2.51–5.69) | 2.47 (2.02–3.81) | –1.323 | 0.186 |
Data expressed as median (interquartile ranges) or n. –: Not applicable. ART: Antiretroviral therapy; NK: Natural killer cell therapy; HIV: human immunodeficiency virus.